International Journal of Clinical Oncology

, Volume 20, Issue 6, pp 1122–1129 | Cite as

Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations

  • Yuhei Yokoyama
  • Makoto SonobeEmail author
  • Tetsu Yamada
  • Masaaki Sato
  • Toshi Menju
  • Akihiro Aoyama
  • Toshihiko Sato
  • Fengshi Chen
  • Mitsugu Omasa
  • Hiroshi Date
Original Article



The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib is an effective treatment for recurrent or advanced lung cancer harboring EGFR gene mutations, and has improved progression-free survival in several clinical trials. However, the effect of gefitinib treatment for recurrent lung cancers with EGFR gene mutations after complete resection and the influence of the timing of such treatment have not been fully elucidated in a practical setting.


We investigated 64 patients (median age: 68 years; men: 22; women: 42; adenocarcinoma: 61; adenosquamous cell carcinoma: 2; combined large cell neuroendocrine carcinoma: 1) with recurrent lung cancer after complete resection who received gefitinib for the recurrent lesions and in whom the tumors had EGFR gene mutations. Progression-free survival, response rate, and safety were analyzed.


Complete response and partial response were achieved in 2 patients and in 42 patients, respectively (objective response rate: 69 %). Stable disease was obtained in 16 patients, the disease control rate was 94 %, and median progression-free survival was 16 months. The timing of gefitinib treatment (first line, second line, or later) and the type of EGFR gene mutation present did not influence progression-free survival. However, a smaller number of recurrent sites at the start of gefitinib treatment was linked to better progression-free survival. Hematologic and nonhematologic toxicities were generally mild, but 1 patient experienced interstitial lung disease.


Our results suggest that gefitinib treatment for recurrent lung cancer with gene EGFR mutations is a useful option in a practical setting, irrespective of the timing of such treatment and the type of EGFR gene mutation present.


Lung cancer Epidermal growth factor receptor Postoperative recurrence Gefitinib 



This study was not supported by any fund, trader, or manufacturer.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Masuda M, Kuwano H, Okumura M et al; Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery (2014) Thoracic and cardiovascular surgery in Japan during 2012: annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 62:734–764Google Scholar
  2. 2.
    Sonobe M, Yamada T, Sato M et al (2014) Identification of subsets of patients with favorable prognosis after recurrence in completely resected non-small cell lung cancer. Ann Surg Oncol 21:2546–2554CrossRefPubMedGoogle Scholar
  3. 3.
    Non-Small Cell Lung Cancer Collaborative Group (2010) Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 5:CD007309. doi: 10.1002/14651858.CD007309.pub2
  4. 4.
    Lee CK, Brown C, Gralla RJ et al (2013) Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 105:595–605CrossRefPubMedGoogle Scholar
  5. 5.
    Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139CrossRefPubMedGoogle Scholar
  6. 6.
    Paez JG, Jänne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500CrossRefPubMedGoogle Scholar
  7. 7.
    Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957CrossRefPubMedGoogle Scholar
  8. 8.
    Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388CrossRefPubMedGoogle Scholar
  9. 9.
    Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121–128CrossRefPubMedGoogle Scholar
  10. 10.
    Fukuoka M, Wu YL, Thongprasert S et al (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29:2866–2874CrossRefPubMedGoogle Scholar
  11. 11.
    Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735–742CrossRefPubMedGoogle Scholar
  12. 12.
    Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246CrossRefPubMedGoogle Scholar
  13. 13.
    Furukawa K, Ishida J, Inagaki M et al (2012) A population-based study of gefitinib in patients with postoperative recurrent non-small cell lung cancer. Exp Ther Med 3:53–59PubMedCentralPubMedGoogle Scholar
  14. 14.
    Mitsudomi T, Kosaka T, Endoh H et al (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patient with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23:2513–2520CrossRefPubMedGoogle Scholar
  15. 15.
    Okami J, Taniguchi K, Higashiyama M et al (2007) Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer. Oncology 72:234–242CrossRefPubMedGoogle Scholar
  16. 16.
    Katayama T, Matsuo K, Kosaka T et al (2010) Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: a retrospective case-matching cohort study. Surg Oncol 19:e144–e149Google Scholar
  17. 17.
    Sonobe M, Kobayashi M, Ishikawa M et al (2012) Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas. Ann Surg Oncol 19(Suppl 3):S347–S354CrossRefPubMedGoogle Scholar
  18. 18.
    Travis WD, Brambilla E, Muller-Hermelink HK et al (2004) World Health Organization classification of tumours: pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC, LyonGoogle Scholar
  19. 19.
    Vallières E, Shepherd FA, Crowley J et al (2009) International Association for the Study of Lung Cancer International Staging Committee and participating institutions. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 4:1049–1059Google Scholar
  20. 20.
    Sonobe M, Manabe T, Wada H et al (2005) Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer 93:355–363PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Satoh H, Inoue A, Kobayashi K et al (2011) Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations. J Thorac Oncol 6:1413–1417CrossRefPubMedGoogle Scholar
  22. 22.
    Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10PubMedGoogle Scholar
  23. 23.
    Niibe Y, Hayakawa K (2010) Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol 40:107–111PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Locatelli-Sanchez M, Couraud S, Arpin D et al (2013) Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18–21 sequencing results of 753 patients and subsequent clinical outcomes. Lung 191:491–499CrossRefPubMedGoogle Scholar
  25. 25.
    Yamada K, Takayama K, Kawakami S et al (2013) Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803). Jpn J Clin Oncol 43:629–635CrossRefPubMedGoogle Scholar
  26. 26.
    Sequist LV, Yang JC, Yamamoto N et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327–3334CrossRefPubMedGoogle Scholar
  27. 27.
    Rosell R, Moran T, Queralt C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958–967CrossRefPubMedGoogle Scholar
  28. 28.
    Inoue A, Kobayashi K, Maemondo M et al (2013) Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 24:54–59CrossRefPubMedGoogle Scholar
  29. 29.
    Ando M, Okamoto I, Yamamoto N et al (2006) Predicitive factors for interstitial lung disease, anti-tumor response and survival in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 24:2549–2556CrossRefPubMedGoogle Scholar
  30. 30.
    Kudoh S, Kato H, Nishiwaki Y et al (2008) Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 2008(177):1348–1357CrossRefGoogle Scholar
  31. 31.
    Nakagawa M, Nishimura T, Teramukai S et al (2009) Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer—a retrospective analysis: JMTO LC03-02. BMC Res Notes 2:157. doi: 10.1186/1756-0500-2-157 PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2015

Authors and Affiliations

  • Yuhei Yokoyama
    • 1
  • Makoto Sonobe
    • 1
    Email author
  • Tetsu Yamada
    • 1
  • Masaaki Sato
    • 1
  • Toshi Menju
    • 1
  • Akihiro Aoyama
    • 1
  • Toshihiko Sato
    • 1
  • Fengshi Chen
    • 1
  • Mitsugu Omasa
    • 1
  • Hiroshi Date
    • 1
  1. 1.Department of Thoracic SurgeryKyoto University HospitalKyotoJapan

Personalised recommendations